ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,035.69
-1.57%
Dow Jones
37,815.92
-1.49%
US Dollar vs MXN
17.13868
-0.08%
Brent Oil
85.44
-0.53%
Bitcoin
59,148.39
-2.40%
Registration Strip Icon for charts Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Celldex Therapeutics Inc (CLDX)

  7. Celldex Therapeutics Inc (CLDX) Noticias

CLDX Celldex Therapeutics Inc

37.42
0.42 (1.14%)
30 Abr 2024 - Cerrado
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Celldex Therapeutics Inc CLDX NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
Upgrade Icon
0.42 1.14% 37.42 19:00:00
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
36.74 36.35 38.15 37.42 37.00
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
17/4/202407:01GLOBECelldex Announces Completion of Enrollment in Phase 2 Study..
08/3/202406:00GLOBECelldex Therapeutics to Participate in the Leerink Partners..
05/3/202409:30GLOBECelldex Therapeutics to Present at TD Cowen’s 44th Annual..
05/3/202409:10GLOBECelldex Therapeutics Announces Closing of Public Offering of..
01/3/202415:10EDGAR2Form 8-K - Current report
01/3/202415:09EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
29/2/202420:14GLOBECelldex Therapeutics Announces Pricing of Upsized $400..
28/2/202415:10EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
28/2/202415:01GLOBECelldex Therapeutics Announces Proposed Public Offering of..
26/2/202407:18EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
26/2/202406:05EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
26/2/202406:01EDGAR2Form 8-K - Current report
26/2/202406:01GLOBECelldex Reports Fourth Quarter and Year End 2023 Financial..
24/2/202413:05GLOBECelldex Therapeutics Presents Positive 12 Week Results from..
15/2/202415:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/2/202415:17EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
14/2/202411:52EDGAR2Form SC 13G - Statement of acquisition of beneficial..
14/2/202410:48EDGAR2Form SC 13G - Statement of acquisition of beneficial..
14/2/202406:38EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
13/2/202408:41EDGAR2Form SC 13G - Statement of acquisition of beneficial..
08/2/202409:11EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
06/2/202415:01GLOBECelldex to Participate in the Guggenheim Healthcare Talks..
05/2/202407:01GLOBECelldex Announces Upcoming Presentation of Barzolvolimab..
04/1/202415:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/11/202315:15GLOBECelldex Therapeutics to Present at 6th Annual Evercore ISI..
20/11/202315:15EDGAR2Form SC 13G - Statement of acquisition of beneficial..
08/11/202316:03EDGAR2Form 8-K - Current report
08/11/202316:01EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
07/11/202322:15GLOBECelldex Therapeutics Announces Pricing of Public Offering of..
07/11/202315:01EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
07/11/202315:01GLOBECelldex Therapeutics Announces Proposed Public Offering of..
06/11/202308:00EDGAR2Form 8-K - Current report
06/11/202305:30GLOBECelldex Therapeutics Announces Positive Topline Results from..
05/11/202314:00GLOBECelldex Therapeutics Presents Positive Data from Prurigo..
03/11/202315:01EDGAR2Form S-3ASR - Automatic shelf registration statement of..
02/11/202315:06EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
02/11/202315:01EDGAR2Form 8-K - Current report
02/11/202315:01GLOBECelldex Reports Third Quarter 2023 Financial Results and..
26/9/202306:01GLOBECelldex Announces Acceptance of Abstract for Barzolvolimab..
25/9/202307:31GLOBECelldex Therapeutics to Present at Cantor Global Healthcare..
08/8/202315:06EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/8/202315:01EDGAR2Form 8-K - Current report
08/8/202315:01GLOBECelldex Reports Second Quarter 2023 Financial Results and..
11/7/202307:01GLOBECelldex Announces Completion of Enrollment in Phase 2 Study..
06/7/202307:01GLOBECelldex Announces First Patient Dosed in Phase 2 Study of..
10/6/202309:45GLOBECelldex Therapeutics Presents Positive Data from..
08/6/202315:01GLOBECelldex Therapeutics Announces Upcoming Barzolvolimab..
02/6/202307:01GLOBECelldex Therapeutics to Present at Jefferies Healthcare..
31/5/202307:01GLOBECelldex Announces First Patient Dosed in Phase 1 Study of..
15/5/202307:01GLOBECelldex Therapeutics Presents Positive Preclinical Data from..

Su Consulta Reciente

NASDAQ
CLDX
Celldex Therapeutics
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados